Peptide agent against multi-resistant bacteria

Researchers from the University of Regensburg have developed a peptide with strong antimicrobial activity against carbapanem resistant gram-negative bacteria, which are responsible for a large number of deaths annually. The antimicrobial peptide kills bacteria within hours, also destroying non-replicating bacteria. The peptide strongly reduces inflammation and is therefore especially suitable to improve outcome in septic patients.
Life Sciences
Therapeutics
Reference
b81112
IP right year
2022
IP status
PCT application filed. EP and US pending
Patentee
University of Regensburg
Contact
Charlotte Federhen

Challenge and innovation

Antimicrobial resistance (AMR) is globally rising over the last decades, partly due to over- or misuse of antibiotics. In 2019, over 3 million deaths were associated with AMR globally. Thereby, the Gram-negative bacteria Escherichia coli, Pseudomonas aeruginosa and Acinetobacter baumannii were within the top six pathogens causing death. Around 8% of patients infected with the aforementioned, resistant pathogens will not survive.

The new peptide-based antimicrobial agent based on an optimized form of the scorpion fish protein BPI (scoBPI) shows very high anti-inflammatory potency towards the endotoxic activity of lipopolysaccharides and a bactericidal activity at nanomolar concentrations against carbapenem-resistant P. aeruginosa, E. coli and A. baumannii. Since the activity of the optimized scoBPI is mediated via membrane perturbation, common resistance mechanisms mediated by e.g. porin loss, efflux pumps and antibiotic-binding or -deactivating proteins do not affect the activity of the antimicrobial peptide.

Talk to an expert

Interested in learning more about this technology offer, exploring potential applications or discussing a possible collaboration? Get in touch to learn more.